JSPR vs. SOPH, SLDB, TNYA, OCGN, MGTX, CRBU, TCRX, AURA, AVXL, and DCGO
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include SOPHiA GENETICS (SOPH), Solid Biosciences (SLDB), Tenaya Therapeutics (TNYA), Ocugen (OCGN), MeiraGTx (MGTX), Caribou Biosciences (CRBU), TScan Therapeutics (TCRX), Aura Biosciences (AURA), Anavex Life Sciences (AVXL), and DocGo (DCGO). These companies are all part of the "medical" sector.
Jasper Therapeutics (NASDAQ:JSPR) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.
Jasper Therapeutics presently has a consensus target price of $64.29, suggesting a potential upside of 192.34%. SOPHiA GENETICS has a consensus target price of $8.00, suggesting a potential upside of 60.97%. Given Jasper Therapeutics' higher probable upside, research analysts plainly believe Jasper Therapeutics is more favorable than SOPHiA GENETICS.
Jasper Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -126.63%. SOPHiA GENETICS's return on equity of -47.40% beat Jasper Therapeutics' return on equity.
79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Jasper Therapeutics received 9 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. Likewise, 83.33% of users gave Jasper Therapeutics an outperform vote while only 72.73% of users gave SOPHiA GENETICS an outperform vote.
Jasper Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 7 articles in the media. Jasper Therapeutics' average media sentiment score of 0.49 beat SOPHiA GENETICS's score of 0.05 indicating that Jasper Therapeutics is being referred to more favorably in the media.
Jasper Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Summary
Jasper Therapeutics beats SOPHiA GENETICS on 10 of the 15 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
